Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2019: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2018: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
|
Outline of Final Research Achievements |
We focused on the diversity of albumin molecules as a disease-progressing factor of the chronic kidney disease. We investigated 1) the molecular mechanism of skeletal muscle atrophy induced by uremic substances and 2) its therapeutic strategy, 3) the molecular mechanism of secondary hyperparathyroidism (SHPT)-induced hyperuricemia, and 4) the inhibition of CYP3A expression in SHPT, and 5) the molecular mechanism of renal tubular injury associated with renal fatty acid fluctuations, then found that indoxyl sulfate, parathyroid hormone and oxidized albumin were identified as negative humoral factors in chronic kidney disease. We also proposed a therapeutic target based on their molecular mechanism.
|